CA2820877A1 - Novel 19-nor-steroids and their use for treating progesterone-dependent conditions - Google Patents

Novel 19-nor-steroids and their use for treating progesterone-dependent conditions Download PDF

Info

Publication number
CA2820877A1
CA2820877A1 CA2820877A CA2820877A CA2820877A1 CA 2820877 A1 CA2820877 A1 CA 2820877A1 CA 2820877 A CA2820877 A CA 2820877A CA 2820877 A CA2820877 A CA 2820877A CA 2820877 A1 CA2820877 A1 CA 2820877A1
Authority
CA
Canada
Prior art keywords
compound
alkyl
salt
accordance
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2820877A
Other languages
English (en)
French (fr)
Inventor
Joseph S. Podolski
Ronald D. Wiehle
Original Assignee
Allergan Pharmaceuticals International Ltd
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2010/062068 external-priority patent/WO2011119194A1/en
Application filed by Allergan Pharmaceuticals International Ltd, Repros Therapeutics Inc filed Critical Allergan Pharmaceuticals International Ltd
Publication of CA2820877A1 publication Critical patent/CA2820877A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
CA2820877A 2010-12-23 2011-09-08 Novel 19-nor-steroids and their use for treating progesterone-dependent conditions Abandoned CA2820877A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/US2010/062068 WO2011119194A1 (en) 2010-03-22 2010-12-23 Compositions and methods for non-toxic delivery of antiprogestins
USPCT/US10/062068 2010-12-23
PCT/US2011/050859 WO2012087389A1 (en) 2010-12-23 2011-09-08 Novel 19-nor-steroids and their use for treating progesterone-dependent conditions

Publications (1)

Publication Number Publication Date
CA2820877A1 true CA2820877A1 (en) 2012-06-28

Family

ID=44681424

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2820877A Abandoned CA2820877A1 (en) 2010-12-23 2011-09-08 Novel 19-nor-steroids and their use for treating progesterone-dependent conditions

Country Status (13)

Country Link
US (1) US20130274234A1 (https=)
EP (1) EP2655394A1 (https=)
JP (2) JP2014500316A (https=)
KR (1) KR20130132955A (https=)
CN (1) CN103403017A (https=)
AU (1) AU2011345341B2 (https=)
CA (1) CA2820877A1 (https=)
MX (1) MX2013006732A (https=)
NZ (1) NZ612295A (https=)
SG (1) SG191207A1 (https=)
UA (1) UA113283C2 (https=)
WO (1) WO2012087389A1 (https=)
ZA (1) ZA201304381B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2872644A1 (en) 2012-05-31 2013-12-05 Allergan Pharmaceuticals International Limited Formulations and methods for vaginal delivery of antiprogestins
US9545411B2 (en) * 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
JP6591447B2 (ja) * 2014-05-05 2019-10-16 レプロス セラピューティクス インコーポレイティド 抗プロゲスチンの膣内送達用の製剤と方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
EP0163696B1 (en) 1983-11-14 1992-11-25 Columbia Laboratories, Inc. Use of a bioadhesive
FR2573657B1 (fr) * 1984-11-29 1989-05-12 Roussel Uclaf Produit comprenant une substance antiprogestomimetique et une substance uterotonique
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
AU710139B2 (en) * 1996-05-01 1999-09-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The 21-substituted progesterone derivatives as new antiprogestational agents
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
AU4584901A (en) * 2000-03-17 2001-10-15 Us Gov Health & Human Serv Structural modification of 19-norprogesterone i: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
AU2007327707B2 (en) * 2006-10-24 2012-07-12 Allergan pharmaceuticals International Ltd. Compositions and methods for suppressing endometrial proliferation
WO2009061569A1 (en) * 2007-11-05 2009-05-14 Repros Therapeutics Inc. Compositions and methods for treating dysfunctional uterine bleeding
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
TWI539953B (zh) * 2008-04-28 2016-07-01 瑞波若斯治療學公司 用於治療乳癌之組成物和方法

Also Published As

Publication number Publication date
JP2014500316A (ja) 2014-01-09
MX2013006732A (es) 2013-07-17
AU2011345341B2 (en) 2016-10-20
CN103403017A (zh) 2013-11-20
KR20130132955A (ko) 2013-12-05
JP2016180004A (ja) 2016-10-13
WO2012087389A1 (en) 2012-06-28
ZA201304381B (en) 2014-03-26
SG191207A1 (en) 2013-07-31
US20130274234A1 (en) 2013-10-17
UA113283C2 (xx) 2017-01-10
EP2655394A1 (en) 2013-10-30
AU2011345341A1 (en) 2013-07-04
NZ612295A (en) 2014-07-25

Similar Documents

Publication Publication Date Title
US20150203526A1 (en) Novel 19-nor-steroids and their use for treating progesterone- dependent conditions
AU2011345341B2 (en) Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
CA2888377C (en) Methods and compositions for treating progesterone-dependent conditions
HK1191339A (en) Novel 19-nor-steroids and their use for treating progesterone-dependent conditions
HK1240094A (en) Compositions and methods for non-toxic delivery of mifepristone
HK1240094A1 (en) Compositions and methods for non-toxic delivery of mifepristone
HK1240111A (en) Compositions and methods for non-toxic delivery of antiprogestins
HK1240111A1 (en) Compositions and methods for non-toxic delivery of antiprogestins
HK1181394A (en) Compositions and methods for non-toxic delivery of antiprogestins

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160818

FZDE Discontinued

Effective date: 20190827